Alpha Tau Medical is a Jerusalem-based brand that focuses on the development and commercialization of DaRT (Diffusing Alpha-Emitters Radiation Therapy) for the treatment of solid cancer tumors. Founded in 2016 by CEO Uzi Sofer, Alpha Tau is committed to bringing the innovative alpha radiation technology to cancer patients worldwide. Their groundbreaking research has led to significant advancements in the field of cancer treatment.

Alpha Tau has conducted several clinical trials and published their results in prestigious medical journals, receiving great enthusiasm from the medical community. They have also received FDA Breakthrough Device Designation for the treatment of skin and oral cavity cancers, as well as recurrent glioblastoma multiforme. In partnership with renowned medical and educational institutions globally, Alpha Tau continues to conduct clinical and pre-clinical studies.

They are also exploring the potential use of Alpha DaRT technology for various cancers, such as breast, pancreas, lung, and prostate cancers. Overall, Alpha Tau Medical strives to revolutionize the treatment of solid tumors, providing new options for patients with limited treatment options and poor prognosis. With their dedication to research and collaboration, they aim to make a positive impact on the lives of cancer patients worldwide